Quanterix Corp.

Quanterix Corp. is a publicly traded life sciences company, trading on NASDAQ under the ticker QTRX. Founded in 2007, the company is headquartered in Billerica, Massachusetts. As of May 2026, Quanterix has a market cap of approximately $130-$160 million and employs around 450-475 people. Its annual revenue in 2025 was reported as approximately $138.9 million.

Quanterix specializes in developing and marketing ultra-sensitive digital immunoassay platforms for life sciences research and diagnostics. Their core offering is the proprietary Simoa (Single Molecule Array) technology, which enables the detection and quantification of protein biomarkers at extremely low concentrations. The company's products include Simoa instruments (such as the HD-X, SR-X, and SP-X), assay kits, and related consumables. Quanterix also provides contract research services and clinical laboratory testing services through its Accelerator Laboratory, focusing on therapeutic areas like neurology, oncology, immunology, cardiology, and infectious disease.

Quanterix appears to be an operating company that has been a defendant in patent litigation. The company has been involved in 1 tracked case as a defendant and 0 as a plaintiff, suggesting a posture of defending its technology rather than asserting patents against others.

The notable case involving Quanterix is Fujirebio Diagnostics, Inc. v. Quanterix Corp., an inter partes review (IPR) filed at the Patent Trial and Appeal Board (PTAB) on March 7, 2025. This PTAB case is related to a lawsuit filed by Fujirebio Diagnostics, Inc. in the U.S. District Court for the District of Delaware in May 2025. Fujirebio sought a ruling that its Alzheimer's disease blood test, the Lumipulse plasma assay, does not infringe Quanterix's U.S. Patent No. 11,275,092, which covers methods for detecting tau protein in blood. The PTAB case itself challenged the patentability of Quanterix's patent, citing prior art related to digital ELISA and tau protein biomarker detection.